loading page

  • +12
  • Heimo Breiteneder,
  • Yaqi Peng,
  • Ioana Agache,
  • Zuzana Diamant,
  • Thomas Eiwegger,
  • Wytske Fokkens,
  • Claudia Traidl-Hoffmann,
  • Kari Nadeau,
  • Robyn O'Hehir,
  • Liam O'Mahony,
  • Oliver Pfaar,
  • Maria Torres,
  • De Yun Wang,
  • Luo Zhang,
  • Cezmi Akdis
Heimo Breiteneder
Medical University of Vienna

Corresponding Author:[email protected]

Author Profile
Yaqi Peng
Swiss Institute of Allergy and Asthma Research
Author Profile
Ioana Agache
Transylvania University of Brasov
Author Profile
Zuzana Diamant
Institute for Clinical Science, Skane University Hospital, Lund University
Author Profile
Thomas Eiwegger
The Hospital for Sick Children
Author Profile
Wytske Fokkens
University of Amsterdam
Author Profile
Claudia Traidl-Hoffmann
Institute of Environmental Medicine, UNIKA-T
Author Profile
Kari Nadeau
Stanford University
Author Profile
Robyn O'Hehir
The Alfred Hospital
Author Profile
Liam O'Mahony
University College Cork National University of Ireland
Author Profile
Oliver Pfaar
University Hospital Marburg, Philipps-Universit├Ąt Marburg, Marburg, Germany.
Author Profile
Maria Torres
Regional University Hospital of Malaga-IBIMA-UMA-BIONAND-ARADyAL
Author Profile
De Yun Wang
Yong Loo Lin School of Medicine, National University of Singapore
Author Profile
Luo Zhang
Beijing TongRen Hospital, Capital Medical University,
Author Profile
Cezmi Akdis
University of Zurich
Author Profile


Modern healthcare requires a proactive and individualized response to diseases, combining precision diagnosis and personalized treatment. Accordingly, the approach to patients with allergic diseases encompasses novel developments in the area of personalized medicine, disease phenotyping and endotyping and the development and application of reliable biomarkers. A detailed clinical history and physical examination followed by the detection of IgE immunoreactivity against specific allergens still represents the state of the art. However, nowadays, further emphasis focuses on the optimization of diagnostic and therapeutic standards and a large number of studies have been investigating the biomarkers of allergic diseases, including asthma, atopic dermatitis, allergic rhinitis, food allergy, urticaria and anaphylaxis. Various biomarkers have been developed by omics technologies, some of which lead to a better classification of the distinct phenotypes or endotypes. The introduction of biologicals to clinical practice increases the need for biomarkers for patient selection, prediction of outcomes and monitoring, to allow for an adequate choice of the duration of these costly and long-lasting therapies. Escalating healthcare costs together with questions on the efficacy of the current management of allergic diseases requires further development of a biomarker-driven approach. Here, we review biomarkers in diagnosis and treatment of asthma, atopic dermatitis, allergic rhinitis, viral infections, chronic rhinosinusitis, food allergy, drug hypersensitivity and allergen-immunotherapy with a special emphasis on specific IgE, microbiome and epithelial barrier. In addition, EAACI guidelines on biologicals are discussed within the perspective of biomarkers.
20 Jul 2020Submitted to Allergy
21 Jul 2020Submission Checks Completed
21 Jul 2020Assigned to Editor
21 Jul 2020Reviewer(s) Assigned
04 Aug 2020Review(s) Completed, Editorial Evaluation Pending
04 Aug 2020Editorial Decision: Revise Minor
25 Aug 20201st Revision Received
26 Aug 2020Submission Checks Completed
26 Aug 2020Assigned to Editor
26 Aug 2020Review(s) Completed, Editorial Evaluation Pending
28 Aug 2020Editorial Decision: Accept